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inter seasonal affective disorder (SAD) is a
mood disorder characterized by the predictable onset of
depression in the fall/winter months,with spontaneous
remissions in the spring/summer period.
1 The typical
patient with SAD is a premenopausal woman who expe-
riences carbohydrate craving,hypersomnia,and promi-
nent fatigue during winter depressive episodes.
1 Many
adults experience similar but milder vegetative symptoms
in the fall/winter months,
2,3 often referred to as “subsyn-
dromal SAD.”This suggests that seasonality may be a
dimensional process rather than a discrete syndrome.
Based on the energy-conserving nature of the core symp-
toms of SAD,various evolutionary theories of SAD and
seasonality have been proposed.
4-8 The possibility that
obesity in the context of SAD might reflect a “seasonal
thrifty phenotype”has also been suggested.
9
To date, research on the biology of SAD has had two
major foci. One major body of work has attempted to
delineate one or more chronobiological factors con-
tributing to SAD and seasonality,with an emphasis on
circadian rhythms,melatonin,and photoperiodic mecha-
nisms.The second major body of work has used a variety
of approaches to examine other brain processes that
might play a role in SAD,with a primary focus on major
brain neurotransmitters such as serotonin,norepineph-
rine,and dopamine.Ultimately,as with other psychiatric
illnesses,it might be best to consider SAD as a complex
disorder that results from the interaction of several vul-
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This review summarizes research on the chronobiology
and neurobiology of winter seasonal affective disorder
(SAD), a recurrent subtype of depression characterized
by a predictable onset in the fall/winter months and
spontaneous remission in the spring/summer period.
Chronobiological mechanisms related to circadian
rhythms, melatonin, and photoperiodism play a signifi-
cant role in many cases of SAD, and treatment of SAD
can be optimized by considering individual differences
in key chronobiological markers. Converging evidence
also points to a role for the major monoamine neuro-
transmitters serotonin, norepinephrine, and dopamine
in one or more aspects of SAD. Ultimately, as with other
psychiatric illnesses, SAD is best considered as a complex
disorder resulting from the interaction of several vul-
nerability factors acting at different levels, the various
genetic mechanisms that underlie them, and the physi-
cal environment. Models of SAD that emphasize its
potential role in human evolution will also be discussed.   
© 2007, LLS SAS Dialogues Clin Neurosci. 2007;9:315-324ous genetic mechanisms that underlie them (Figure 1).
The following paragraphs will summarize work to date
on the chronobiology/neurobiology of SAD, and are
followed by a general discussion and directions for
future work.
Chronobiological mechanisms
Photoperiodism and day length 
As the most distinguishing feature of SAD is its inherent
rhythmicity and sensitivity to environmental light condi-
tions,chronobiological mechanisms have been a major
focus for research in this area.Based on the marked sim-
ilarity between the core symptoms of SAD and energy-
conserving strategies implemented by various species at
northern latitudes, the “latitude” or “photoperiodic”
hypothesis of SAD was one of the first to be examined.
According to this hypothesis,if one could demonstrate a
clear association between the prevalence of SAD and
increasing latitude,this would strongly support the notion
that biological adaptations tied to the short days of win-
ter are the primary factor that distinguishes SAD from
other mood disorders.In one of the first large studies to
test this hypothesis, the Seasonal Pattern Assessment
Questionnaire (SPAQ),
10 a screening tool which assesses
the seasonality of six core symptoms of SAD and the
degree to which seasonality is problematic,was mailed to
randomly selected individuals in four areas of the United
States differing in latitude.
11 It was found that rates of
winter SAD and subsyndromal SAD were significantly
higher at higher latitudes,while no correlation was found
between latitude and summer SAD,a rarer form of sea-
sonal depression thought to be mediated by heat and
humidity.The authors concluded that winter SAD was
likely triggered by light deprivation during the short
days of fall and winter associated with more northern
latitudes.
11
Michalak and Lam reviewed 22 studies performed in
either the general population or in specific subpopula-
tions to look at the relationship of latitude to SAD.
12 In
the general population in particular,there was a correla-
tion of 0.66 between latitude and rates of SAD, which
would support the latitude hypothesis overall.However,
one of the paradoxes in studying a possible relationship
between SAD and latitude is that over the course of
time,populations that are less impacted by the short days
of winter may choose to remain at a northern latitude,
while more sensitive populations might be expected to
migrate South.If so,this would likely weaken the corre-
lation between latitude and rates of SAD in large epi-
demiological studies.One example of this potential con-
founding factor is demonstrated in a study of SAD and
seasonality in Icelanders. Magnusson and Axelsson
examined the prevalence of SAD in Icelanders who had
migrated to Manitoba,Canada,and found their rates of
SAD to be much lower than in other ethnic populations
living at a similar latitude.
13 Based on this finding, the
authors concluded that Icelanders might be genetically
protected from SAD.This demonstrates the importance
of considering gene-environment interactions when ana-
lyzing prevalence rates for SAD at a given location.A
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SAD seasonal affective disorder
SCN suprachiasmatic nucleus
Figure 1. Schematic model of the biology of seasonal affective disorder (SAD). SAD is depicted as a complex phenotype shaped by multiple vulnera-
bility factors acting at the level of biological rhythms, mood and appetite regulation, light sensitivity, etc. Each of these intermediate pheno-
types is in turn shaped by multiple genes. As with other complex phenotypes, it is unlikely that a single vulnerability factor or gene can account
for SAD—rather it is the interaction of multiple factors interacting with the environment that shapes the ultimate phenotype.
Biological rhythms
Genes A,B,C Genes D,E,F Genes G,H,I Genes J,K,L
Mood regulation
SAD
Increased eating Light sensitivitysimilar finding was reported by Levitt and Boyle
14 in a
Canadian population.In this study,eight different strata
were identified in the Province of Ontario,based on lat-
itude.A negative correlation between latitude and rates
of SAD was found,contradictory to the prediction of the
latitude hypothesis.The authors themselves noted the
possibility that this could be explained by a tendency of
genetically protected individuals to remain at more
northern latitudes,whereas others would tend to migrate
southward.Another factor to consider in studies of this
type is that relative to urban dwellers,rural communities
may have significantly more exposure to natural light in
the wintertime, based on their daily routines. Yet
another complicating factor is local weather conditions,
which might greatly affect light availability independent
of latitude.
Taking these factors into consideration,a robust test of
the latitude hypothesis might require large-scale studies
using within-subject designs to look at seasonal mood
changes in genetically homogenous groups who migrate
North or South.It would be important to study popula-
tions travelling in both directions,as immigration is itself
associated with the risk for depression.A consistent pat-
tern of within-subject increases in seasonality with north-
ern migration above the equator,and decreased season-
ality with the opposite direction of migration,would lend
further support to the latitude hypothesis.
Melatonin
Another strategy to test the photoperiodic hypothesis of
SAD is to study the hormone melatonin, which is
secreted by the pineal gland in response to ambient dark-
ness.In animals,the circadian pacemaker in the suprachi-
asmatic nucleus (SCN) regulates seasonal changes in var-
ious aspects of behavior, including food intake and
reproduction,by transmitting a melatonin signal of day
length.This signal is expressed through the duration of
melatonin secretion at night, which is longer in winter
than in summer.Over the course of the year,the SCN is
able to track changing times of dawn and dusk.Various
central and peripheral sites can respond to the melatonin
signal produced in this way to help an organism adapt to
seasonal environmental conditions.
While the anatomical circuitry that mediates this pho-
toperiodic mechanism is present in humans,
15 its func-
tional significance in our species remains controversial.
With respect to SAD,demonstrating differences in this
system between SAD patients and matched controls
would lend support to the hypothesis that SAD is a
chronobiological disorder tied to changes in the pho-
toperiod across seasons. One approach to examining a
possible photoperiodic model of SAD has been to com-
pare melatonin rhythms in SAD patients and normal con-
trols across the winter and summer seasons.Two studies
failed to show differences in the melatonin rhythm
between SAD patients and controls across seasons,
16,17
although another did report high daytime melatonin lev-
els during winter depressive episodes.
18 In the latter study,
the difference between patients and controls in the win-
ter disappeared both after light treatment and in the sub-
sequent summer.Koorengevel et al
19 used a forced desyn-
chrony protocol to examine unmasked circadian
pacemaker characteristics in SAD.No significant differ-
ences were observed between SAD patients and controls
in the melatonin-derived period across seasons.In a large
sample of patients with SAD and matched healthy vol-
unteers,Wehr et al found that patients with SAD had a
longer duration of nocturnal melatonin secretion in win-
ter than in the summer,while healthy controls did not,
20
which might reflect a vestigial photoperiodic mechanism
present in SAD patients but not controls.The authors
concluded that SAD patients might be able to generate a
biological signal of change of season,similar to that which
is seen in other mammals to regulate seasonal changes in
behavior and reproduction.
Other studies have looked at responsiveness to different
light therapy protocols as a way of testing the photope-
riodic hypothesis.The very first studies of light therapy in
SAD were specifically designed to extend the photope-
riod in winter by giving light exposure both early in the
morning and later in the evening. While this artificial
method of extending the photoperiod did lead to signifi-
cant improvement,subsequent studies showed that such
extension of the photoperiod was not sufficient to treat
SAD,and that early-morning light on its own was effec-
tive in many cases.The latter does not necessarily refute
the photoperiod extension hypothesis,however,in that
early-morning light might still extend the photoperiod by
decreasing the duration of night.
In summary,for the reasons outlined above,testing the
photoperiod or latitude hypothesis of SAD has proven to
be quite challenging methodologically.Taken as a whole,
the data does suggest that over large changes in latitude
there is a positive correlation between higher latitude and
rates of seasonal mood change in the population in gen-
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20 suggests that SAD
patients have a greater seasonal fluctuation in their mela-
tonin rhythm than do normal controls,similar to what is
seen in animals who rely on photoperiodic signals.Light
therapy studies have produced mixed results, although
these could in theory be explained by an ability of morn-
ing light to extend the photoperiod early in the day.
Circadian rhythms and the phase shift hypothesis
In mammals,internal circadian rhythms are generated by
the SCN of the hypothalamus.The periodicity of the SCN
is controlled by a number of cellular proteins which are
coded for by PERIOD (per) genes.Entrainment of inter-
nally generated circadian rhythms to the light-dark cycle
requires one or more time cues,or zeitgebers,such as light.
Light signals are transmitted through the eyes to the SCN
via the retinohypothalamic tract.While it was previously
thought that circadian rhythms were entrained through
light signals coming from the visual system per se,recent
studies have identified a novel class of intrinsically light
sensitive retinal ganglion cells that send axonal projections
to the SCN independently of rod and cone photorecep-
tors.
21These SCN-projecting cells express newly discovered
photopigments such as melanopsin
22 and cryptochromes.
23
Circadian rhythms have been an important focus for
SAD research.Lewy et al proposed a phase shift hypoth-
esis of SAD,suggesting that seasonal depression occurs
when intrinsic circadian rhythms,such as the melatonin
and temperature rhythms,are phase delayed relative to
the external clock and/or sleep/wake cycle.
24According
to this model,light therapy should exert its therapeutic
effect by correcting these phase abnormalities.A further
prediction of this hypothesis is that morning light ther-
apy should be superior to evening light therapy for the
larger group of SAD patients who start with a phase
delay,based on the ability of morning light to cause a cor-
rective phase advance.This contrasts the effect of evening
light,which would further delay circadian phase.
Regarding the first component of the phase shift hypoth-
esis,several studies have looked for a phase delay in cir-
cadian rhythms in SAD patients relative to controls.
While both positive and negative studies have been
reported,
16,25-32 it could be argued that one or more mask-
ing effects may have limited some of these results.One
study that used a stringent constant routine protocol to
minimize the problem of masking effects did find circa-
dian phase delays in a small number of hypersomnic
patients.
33 However,given the intensive nature of the con-
stant routine protocol, dim light melatonin onset
(DLMO),which can be measured using salivary samples,
is a more practical means of assessing circadian phase in
larger samples.Using this methodology,a recent study in
68 SAD patients found that 71% were in fact phase
delayed,while 29% were phase advanced,suggesting that
the phase advanced subtype might be more common
than previously thought.
34
Regarding the question of whether light therapy works
by correcting a phase delay in circadian rhythms, two
meta-analyses
35,36 do support the prediction that morning
light,which phase advances circadian rhythms,is more
effective than light administered at other times of day.
Melatonin given in the evening,a different means of pro-
ducing a phase advance, has also been shown to have
therapeutic effects in SAD patients,particularly for sub-
jects having a phase delay at baseline.
34
Other work has shown that while the ability of light to
produce a phase advance contributes to its clinical effi-
cacy,this is not limited to subjects who are phase delayed
to start with.Rather,it is the size of the phase advance
relative to one’s sleep rhythm that is most important,
with the optimal response achieved with light given 8.5
hours after melatonin onset or 2.5 hours after the sleep
midpoint,defined as the midpoint between sleep onset
and time of awakening.
37Yet another study which used
rectal core body temperature as the key dependent mea-
sure found a weak correlation between phase advance
with light and therapeutic response in SAD patients.
38
Taking these various findings into consideration,and giv-
ing additional weight to the more recent studies with
large sample sizes and rigorous methodologies,it would
appear that circadian phase abnormalities do play a role
in many cases of SAD, and that the ability of morning
light to produce a phase advance is an important com-
ponent of its therapeutic effect. While it was initially
thought that only phase-delayed SAD patients would
benefit from this effect,it would now appear that opti-
mizing treatment based on circadian time can benefit a
broader range of patients.
37 Use of the DLMO as a
marker of circadian phase has great potential benefit in
terms of optimizing treatment schedules.
Clock genes, circadian rhythms, and SAD
Another potential focus for future research may be to
identify clock genes which contribute to SAD via altered
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ants related to SAD and seasonality have begun to
emerge.
39 However,as is the case with all genetic associ-
ation studies,replication and clearer delineation of the
relevant phenotypes are needed before firm conclusions
can be drawn.Optimizing light therapy treatment based
on particular clock gene variants is another important
goal for SAD genetics work.
Brain neurotransmitter studies
In parallel with work in nonseasonal depression,a num-
ber of approaches have been implemented to study the
role of brain neurotransmitters, particularly the
monoamines serotonin,norepinephrine,and dopamine,
in the etiology and pathophysiology of SAD.One chal-
lenge in work of this type is to look for changes that dis-
tinguish SAD from other types of depression.
Serotonin
The largest body of work on brain neurotransmitter func-
tion in SAD has focused on the serotonin system.Of the
monoamine neurotransmitters,serotonin has the clear-
est seasonal rhythm in its metabolism and availability,
40-42
with most such measures pointing to decreased
levels/activity in the winter months. To more directly
assess serotonergic function in SAD,various probes of
the serotonin system have been used.Earlier studies used
hormonal responses to challenges with serotonergic ago-
nists to assess the status of serotonin receptors, with
mixed results overall.
43-47 Subjective responses to the drug
may be a better indicator of actual brain receptor func-
tioning in that hormonal responses are mediated at the
level of the pituitary gland.Studies with the nonspecific
serotonin agonist meta-chlorophenyl-piperazine (m-
CPP) have been relatively consistent in this regard,
demonstrating that during depressive episodes, SAD
patients tend to report increased activation or euphoria
relative to controls following administration of this
drug.
43,46,47 These altered subjective responses, which
appear to resolve after light therapy, are likely to be a
state marker of winter depression.Interestingly,a study
of m-CPP in nonseasonal depression demonstrated no
differences in subjective responses in patients compared
with controls,and only minor changes in neuroendrocine
responses,
48 suggesting that altered serotonin receptor
function in SAD may be relatively specific.On the other
hand,the eating disorder bulimia nervosa has also been
associated with altered responses to serotonergic agonists
such as m-CPP,
49-51 suggesting that some serotonin recep-
tor changes may be associated with increased appetitive
behavior,independently of depression,across psychiatric
disorders.It is well established that serotonin has a major
role in suppressing various aspects of feeding behavior.
52
Depletion of tryptophan, the amino-acid precursor of
serotonin,has also been used to assess brain serotoner-
gic functioning in various psychiatric populations.This
uses a specialized diet which includes various amino acids
other than tryptophan.Imaging studies suggest that this
procedure is capable of rapidly lowering brain trypto-
phan levels by over 80% within just a few hours.
53
Tryptophan depletion does not worsen depressive symp-
toms in untreated SAD patients during the fall/winter
period, suggesting a possible floor effect in terms of
decreased serotonergic functioning and lowered mood.
54
However,similar to patients with nonseasonal depres-
sion,
55,56 SAD patients who are in short-term clinical
remission do show a brief relapse of depressive symp-
toms in response to tryptophan depletion.
57,58This proce-
dure may also produce a brief relapse of symptoms when
patients are in their summer remitted state,
59 although
negative findings have also been reported.
60
Tryptophan depletion may have particularly strong
effects in triggering the appetitive symptoms of SAD.
57
Subjective loss of control of eating following tryptophan
depletion has also been demonstrated in recovered
patients with bulimia nervosa,
61 adding further evidence
for serotonergic involvement in the increased eating
behavior manifest in these disorders.The fact that SAD
patients report distinct subjective responses to high-car-
bohydrate meals,
62 which can enhance serotonin turnover
via increased tryptophan uptake into the brain,
63 adds
further support to this hypothesis.
There have been relatively few brain imaging studies
looking at serotonin function in SAD; however, one
study using single photon emission computed tomogra-
phy (SPECT) showed reduced availability of brain sero-
tonin transporters,the proteins responsible for reuptake
of serotonin into presynaptic neurons, in drug-free
patients with SAD during a winter depressive episode.
64
These findings were clearest in the thalamus and hypo-
thalamus,a finding that has also been reported in non-
seasonal atypical depression.
65
Given the large body of evidence linking serotonin dys-
function to SAD,several genetic association studies have
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tributes to one or more aspects of SAD (reviewed by
Sohn and Lam
66). The largest body of work has been
done on the serotonin transporter gene repeat length
polymorphism (5-HTTLPR) which is known to be func-
tional in humans.
67 Initial positive associations between
this gene and SAD and/or seasonality were found
68,69;
however, the largest study to date, using pooled data
from three separate samples,did not find a positive asso-
ciation between 5-HTTLPR and the diagnosis of SAD.
70
One study did find an association between the hypo-
functional s-allele of HTTLPR and the atypical symp-
toms of SAD,
71 providing more evidence that in some
cases,low serotonin activity may contribute to appetitive
symptoms independently of the overall diagnosis of
SAD. A possible link between altered tryptophan
responses and the hypofunctional “s”allele of HTTLPR
has been suggested in nonseasonal depression.
72
However,a similar study in SAD patients was negative.
73
Examining effects of tryptophan depletion in individuals
with differing variants of the tryptophan hydroxylase–2
gene,which is expressed in brain,would also be of great
interest, although no studies of this type have been
reported to date.
Catecholamines
To determine whether catecholamine dysfunction can
also explain the clinical manifestation of SAD,
Neumeister et al administered both tryptophan depletion
and catecholamine depletion protocols,in random order,
to patients with SAD in remission after light therapy.
74
Sham depletions were also included in this protocol.
Both active depletions caused a temporary relapse of
depressive symptoms, demonstrating that cate-
cholamines,in addition to serotonin,are likely to play a
role in SAD.In further support of this hypothesis,cate-
cholamine depletion can also cause a temporary relapse
in depressive symptoms in SAD patients during their
summer remission.
75
Dopamine has unique characteristics that might play a
role in particular aspects of the SAD syndrome. For
example, dopamine is known to play a critical role in
light/dark adaptation at the level of the retina,where it
has a mutually inhibitory relationship with melatonin.
Among the various components of the dopamine system,
the D4 receptor may be of particular interest in this
regard.Electroretinography (ERG) studies suggest that
SAD patients have a reduced B-wave amplitude
76 which
might reflect low retinal dopaminergic activity;strikingly,
virtually the same attenuation of the B-wave response
has been found in D4 knockout mice,who do not express
D4 receptors.
77As a hypofunctional 7-repeat variant of
the D4 gene exon 3 VNTR polymorphism has been well
characterized in humans,
78 a reasonable hypothesis for
future work is that blunted ERGs in patients with SAD
are mediated by this hypofunctional dopamine receptor
gene (DRD4) variant.
While no studies to date have looked at the relationship
between D4 receptors and ocular mechanisms in SAD,
the hypofunctional 7-repeat allele of DRD4 has been
associated with childhood dysphoria and inattention,and
various manifestations of overeating and obesity, in
female SAD probands.
7,9,79 Neuroimaging further points
to decreased availability of striatal dopamine transporter
binding sites in symptomatic patients with SAD.
80 As
both the D4 receptor and dopamine transporter are
expressed in brain areas that comprise the natural reward
pathway,
81 and given the fundamental role of dopamine
in brain reward processes,it is reasonable to hypothesize
that dopamine plays a unique role in the appetitive
symptoms of SAD,distinct from those of serotonin.It is
highly plausible that altered dopamine activity con-
tributes to the rewarding aspects of highly palatable
foods in SAD,while low serotonin activity contributes to
overeating via effects on satiety mechanisms.
Fatigue and low levels of subjective arousal are also
highly characteristic of SAD patients,which could reflect
hypoactivity of both dopamine and norepinephrine in the
brain. One study has shown blunted norepinephrine
responses to a pharmacological challenge in untreated
SAD patients compared with normal controls,
82 while
another has found an increase in plasma levels of norep-
inephrine following light treatment for SAD.
83A nega-
tive correlation between resting cerebrospinal fluid lev-
els of norepinephrine metabolites,and depression ratings
in SAD patients has also been described.
84
Conclusion and future directions
Significant progress has been made on delineating the
chronobiology and neurobiology of SAD and seasonal-
ity, though much more work is needed to refine our
understanding of this syndrome.In terms of chronobio-
logical studies,much of the earlier work was limited by
both small sample sizes and a tendency to consider SAD
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sistencies across studies. More recent work, which has
implemented careful measurement of circadian phase in
larger samples,with a greater allowance for individual
differences in the target phenotypes,has elucidated the
picture of circadian dysregulation in significant sub-
groups of SAD patients. The importance of matching
treatment protocols to a particular individual’s circadian
pattern has been an important clinical advance that has
further emerged from this work.
34,37
Neurotransmitter studies support a role for both sero-
tonin and dopamine in the affective and/or appetitive
symptoms of SAD.In the case of serotonin,there is sig-
nificant evidence for an intrinsic seasonal rhythm of sero-
tonin metabolism and turnover that is likely to contribute
to seasonality of mood and food intake,significant evi-
dence for altered serotonin receptor and transporter
activity in SAD patients during winter depressive
episodes,and clear sensitivity of SAD patients to deple-
tion of the serotonin precursor tryptophan when remit-
ted following light therapy.No strong genetic associations
between SAD and serotonin genes have been found to
date,although much larger studies with greater attention
to intermediate phenotypes,use of multiple markers per
gene,and consideration of gene-gene and gene-environ-
ment interactions are required to examine this question
more robustly.Dopamine dysfunction might contribute
to several aspects of SAD,including altered light respon-
sivity at the level of the retina and both hypoarousal and
overeating at the level of the central nervous system.The
D4 receptor gene is of great interest in this regard,in that
the hypofunctional 7-repeat allele of DRD4 has been
linked to both affective and appetitive symptoms in
SAD.As discussed above,this same allele is an excellent
candidate to study altered ERG responses in this popu-
lation. The fact that this 7R allele has been positively
selected for in recent human evolution
85 adds an intrigu-
ing twist to this story given several evolutionary models
of SAD.
4-9
There are several other areas that hold great promise for
future investigation.For example,in addition to examin-
ing the genetic basis of retinal ERG changes as alluded
to above, there is a great need to study the role of the
melanopsin system,and its genetic and phenotypic vari-
ants, in mediating the circadian changes seen in many
SAD patients.As the genetic and molecular mechanisms
underlying various clock genes becomes clearer,apply-
ing these findings to understand individual differences in
circadian physiology in SAD patients and matched con-
trols should further improve our treatment of these
patients. The use of genetic data to predict treatment
response is largely unexplored to date.
Ultimately,many features of SAD make it an ideal focus
for pathophysiological studies,suggesting that many sig-
nificant new findings will emerge from the next decade
of work in this area.❏
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La cronobiología y la neurobiología del tras-
torno afectivo estacional invernal
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cronobiológicos relacionados con los ritmos circa-
dianos, la melatonina y el fotoperíodo juegan un
papel significativo en muchos casos de TAE, y el tra-
tamiento de este cuadro se puede optimizar al
tener en consideración las diferencias individuales
en los marcadores cronobiológicos clave. También
existen evidencias que apuntan al papel de los prin-
cipales neurotransmisores monoaminérgicos sero-
tonina, noradrenalina y dopamina en uno o más
aspectos del TAE. Últimamente el TAE, como otras
patologías psiquiátricas, se considera más bien un
trastorno complejo que se debe a la interacción de
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troubles affectifs saisonniers de l’hiver
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et la neurobiologie des troubles affectifs saisonniers
(TAS) de l’hiver, un sous-type de dépression récur-
rente caractérisé par un début prévisible en
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temps/été. Des mécanismes chronobiologiques liés
aux rythmes circadiens, la mélatonine et le photo-
périodisme jouent un rôle significatif dans de nom-
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optimisé en tenant compte des différences indivi-
duelles au niveau des marqueurs chronobiologiques.
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ronnement physique. Nous examinerons également
des modèles du TAS qui soulignent le rôle potentiel
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